PRECISION DIAGNOSTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In November 2023, Roche announced the launch of the LightCycler PRO System, based on the established gold standard technology of previous LightCycler Systems. This innovative technology improves performance and usability while closing the gap between translational research and in vitro diagnostics. The LightCycler PRO System expands Roche's molecular PCR testing portfolio, which includes solutions for a wide range of healthcare professionals, including those conducting research and those testing patients for cancer, infectious diseases, and other public health issues.
• In June 2023, Diatech Pharmacogenetics, a provider of molecular diagnostic tools, signed a collaborative agreement with Janssen Pharmaceutica NV, a pharmaceutical business, to improve access to precision medicine for patients with bladder cancer. Diatech Pharmacogenetics, one of Europe's leading precision medicine firms, develops and manufactures In Vitro Diagnostic (IVD) oncology tests for a variety of solid tumours and blood cancers.
• In March 2023, QIAGEN N.V., a multinational provider of sample and assay technologies, announced a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor used to treat acute myeloid leukemia (AML). Under the master collaboration agreement, QIAGEN N.V. will create and validate a real-time in vitro PCR test for detecting IDH1 gene alterations in AML patients' whole blood and bone marrow aspirates.
• In March 2021, Konica Minolta Precision Medicine, Inc. (KMPM), a Konica Minolta Group company, announced a five-year collaboration with Amazon Web Services, Inc. (AWS). As the Preferred Cloud Provider for KMPM, AWS will help the company scale out its LATTICE project globally. LATTICE is a ground-breaking integrated diagnostic data platform that combines genomes, pathology, and radiology data with other important information to identify novel, clinically relevant biomarkers and develop the next generation of diagnostic tests.